Solid Biosciences

About

In 2013, Solid Biosciences was founded by individuals deeply connected to Duchenne muscular dystrophy, driven by an urgent mission to develop meaningful therapies for patients living with this devastating rare disease. What started as a personal crusade to address an unmet medical need has evolved into a precision genetic medicine company advancing a diversified portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases. Today, Solid Biosciences is focused on developing multiple groundbreaking gene therapy programs, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich's ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), and SGT-601 for TNNT2-mediated dilated cardiomyopathy. The company is also pioneering innovative libraries of genetic regulators and enabling technologies with potential to significantly advance gene therapy delivery across the industry. Patient-focused and founded by those directly impacted by Duchenne, Solid's mission is to improve the daily lives of patients living with devastating rare diseases while uniting experts in science, technology, disease management, and care.